Grifols to set up intravenous (IV) solutions manufacturing plant in Nigeria

NIGERIA – Grifols, a global producer of plasma-derived medicines and provider of technologies and services, has announced it will establish an intravenous (IV) solutions production plant in Nigeria.

The plant is to be set up for Dozie and Dozie’s Pharma Nig Ltd., a provider of healthcare products in the country and surrounding region.

When completed in 2024 in southeast Nigeria, the manufacturing installation’s initial phase will produce as many as 5.5 million intravenous solutions bags yearly to be used in hospitals and other healthcare institutions in Nigeria and other African countries.

Grifols Engineering, with broad global experience building advanced, specialized production facilities for the healthcare and biotechnology sectors, will design the plant and provide clean rooms and process equipment.

Sufficient capacity will be incorporated to enable the doubling of output to meet the expected growth in demand.

According to a comprehensive research report by Market Research Future (MRFR), the Intravenous (IV) Solutions market is expected to grow at a significant CAGR of 7.69% from 2021 to 2028.

Escalating cases of diseases like neurological disorder, diabetes, gastrointestinal disorder, and cancer, have fostered the growth of the intravenous solutions industry.

The Centers for Disease Control and Prevention (CDC) reveals that close to 35.2 million Americans were affected by diabetes in 2020, which accounts for roughly 11.5% of the total population in the country.

Diabetes leads to malnourishment among elderly patients, which pushes the need for intravenous solution for replenishment.

However, a smaller number of suppliers, leading to shortage of intravenous solutions could slow down the market growth rate in a few countries, especially in the African region.

“Grifols is extremely pleased to be selected by Dozie and Dozie’s Pharma for a state-of-the-art IV solutions manufacturing plant to enhance healthcare delivery in Nigeria and Western Africa,” said Daniel Fleta, Grifols Chief Industrial Officer.

Grifols strengthened its presence in Africa when in November 2020 it entered into a key strategic alliance with the government of Egypt to develop the local market for plasma-derived therapies, including the opening of 20 plasma centers and the construction of a plasma fractionation plant and a purification and fill-and-finish plant.

Africa will benefit from this advanced infrastructure aimed at strengthening regional self-sufficiency in hemoderivatives.

The company has also designed and established a plasma collection center and modular laboratories in Liberia as part of efforts to combat Ebola, and is completing an IV solutions plant it designed and equipped in Morocco.

Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.